Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome
Go back to Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.73 +0.06 (2.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.67 | 52 Week High | $8.30 | |||
| Open | $2.73 | 52 Week Low | $2.43 | |||
| Day High | $2.78 | P/E | N/A | |||
| Day Low | $2.58 | EPS | $-0.22 | |||
| Volume | 8,914,887 | |||||
